Records how SGLT2 inhibitor medicines are used in adults with congenital heart disease
Studies safety and effects of SGLT2 inhibitor medicines in adults with congenital heart disease.
Plain-language title generated from the registry record
Registry title: Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
Key facts
- Where
- Duisburg, GermanySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The registry is looking for adults born with a heart defect who have started treatment with an SGLT2 inhibitor.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- A congenital heart defect (a heart problem present from birth).
- Earlier treatment
- Must have started treatment with an SGLT2i.
Main reasons for not taking part
- No consent for data collection
Read by machine on 12 November 2026.
Where in Germany
- Heart Center Duisburg (Evangelical Hospital Niederrhein)Duisburg, GermanyContact: Paul Hacke, MD (principal investigator)Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Leiden University Medical Center
- Trial code
- NCT06932081
- Record updated
- 13 February 2026
- Original description
This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.Read full original descriptionShow less
Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i (ACHIEVE-SGLT2i) Registry
This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.
Inclusion: Congenital heart defect; Age ≥ 18 years; Initiated on treatment with an SGLT2i.
Exclusion: No consent for data collection.